Pathological complete response in pancreatic adenocarcinoma with FOLFIRINOX
Authors:
- 1 September 2018
- journal article
- case report
- Published by BMJ in BMJ Case Reports
- Vol. 2018
Abstract
The report describes a patient who presented to our centre with abdominal pain and significant weight loss due to adenocarcinoma of the tail of the pancreas. The cancer was deemed as ‘resectable disease associated with morbid surgical outcomes’ due to the local involvement of the vessels and adjacent organs. Given the patient’s excellent performance status, the patient underwent neoadjuvant chemotherapy with folinic acid, fluorouracil, irinotecan and oxaliplatin to downstage the tumour for less morbid surgical resection. The patient underwent 12 cycles of chemotherapy with serial imaging which demonstrated positive response to treatment and surgical resection was performed. Surgical pathology revealed no residual tumour and imaging was negative for any extrapancreatic tumour metastasis. This is an unusual case as pancreatic malignancy is usually lethal with poor survival outcomes.Keywords
This publication has 14 references indexed in Scilit:
- Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case reportOncology Letters, 2017
- Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and reviewBMC Cancer, 2016
- Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic CancerJAMA Surgery, 2016
- Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2016
- Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic CancerAnnals of Surgical Oncology, 2016
- Management of borderline resectable pancreatic cancerWorld Journal of Gastrointestinal Oncology, 2015
- Pancreatic Ductal Adenocarcinoma Radiology Reporting Template: Consensus Statement of the Society of Abdominal Radiology and the American Pancreatic AssociationRadiology, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Pancreatic adenocarcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2012
- Neoadjuvant Therapy in Pancreatic CancerCancer Investigation, 2007